Topical dapsone and dapsone/adaplene compositions and methods for use thereof
Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder.
1. A topical pharmaceutical composition comprising:
7% w/w to 10% w/w dapsone;
0.1% w/w to 0.3% w/w adapalene;
about 30% w/w to about 40% w/w diethylene glycol monoethyl ether; about 2% w/w to about 6% w/w of a polymeric viscosity builder comprising acrylamide/sodium acryloyldimethyl taurate copolymer; and
water.
2. The composition of claim 1 , wherein the dapsone is present at a concentration of 10% w/w.
3. The composition of claim 2 , wherein the adapalene is present at a concentration of about 0.1% w/w.
4. The composition of claim 3 , wherein the diethylene glycol monoethyl ether is present at a concentration of about 35% w/w.
5. The composition of claim 3 , wherein the diethylene glycol monoethyl ether is present at a concentration of about 40% w/w.
6. The composition of claim 1 , wherein the polymeric viscosity builder is present at a concentration of about 4% w/w.
7. The composition of claim 1 , wherein the topical pharmaceutical composition further comprises methyl paraben.
8. The composition of claim 1 , wherein the topical pharmaceutical composition further comprises ethylene diamine tetraacetic acid (EDTA).
9. A method of treatment of acne vulgaris, the method comprising administration of a topical pharmaceutical composition to a patient in need thereof, the topical pharmaceutical composition comprising:
7% w/w to 10% w/w dapsone;
0.1% w/w to 0.3% w/w adapalene;
about 30% w/w to about 40% w/w diethylene glycol monoethyl ether; about 2% w/w to about 6% w/w of a polymeric viscosity builder comprising acrylamide/sodium acryloyldimethyl taurate copolymer; and
water.
10. The method of claim 9 , wherein the dapsone is present at a concentration of 10% w/w.
11. The method of claim 10 , wherein the adapalene is present at a concentration of 0.1% w/w.
12. The method of claim 11 , wherein the diethylene glycol monoethyl ether is present at a concentration of about 35% w/w.
13. The method of claim 11 , wherein the di ethylene glycol monoethyl ether is present at a concentration of about 40% w/w.
14. The method of claim 9 , wherein the polymeric viscosity builder is present at a concentration of about 4% w/w.